Last reviewed · How we verify
Etakridin (ETHACRIDINE)
Ethacridine (Etakridin) is a marketed drug that uniquely targets telomerase reverse transcriptase, positioning it as a niche player in the antiseptic and antimicrobial market. Its key strength lies in its distinct mechanism of action, which differentiates it from same-class competitors such as cetylpyridinium and chlorhexidine, both of which are either off-patent or soon to be off-patent. The primary risk to Ethacridine's market position is the expiration of its key composition patent in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | ETHACRIDINE |
|---|---|
| Drug class | ethacridine |
| Target | Telomerase reverse transcriptase, Reverse transcriptase, Reverse transcriptase/RNaseH |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- The Efficacy and Safety Assessment of Huafu Shengji Ointment in Patients With Diabetic Foot of Qi Deficiency and Blood Stasis Syndrome (EARLY_PHASE1)
- Clinical Evaluation and Generalized Application of "Qing-Hua-Bu" Three Dynamic Sequential Therapy of Diabetic Ulcer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Etakridin CI brief — competitive landscape report
- Etakridin updates RSS · CI watch RSS